tbuckley/cabot-search huggingface dataset:
Diagnosis of Acute Gout: A Clinical Practice Guideline From the American College of Physicians
Authors: Amir Qaseem, Robert M. McLean, Melissa Starkey, Mary Ann Forciea
Journal: Annals of Internal Medicine (2016)

Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the diagnosis of gout. Methods: This guideline is based on a systematic review of published studies on gout diagnosis, identified using several databases, from database inception to February 2016. Evaluated outcomes included the accuracy of the test results; intermediate outcomes (results of laboratory and radiographic tests, such as serum urate and synovial fluid crystal analysis and radiographic or ultrasonography changes); clinical decision making (additional testing and pharmacologic or dietary management); short-term clinical (patient-centered) outcomes, such as pain and joint swelling and tenderness; and adverse effects of the tests. This guideline grades the evidence and recommendations by using the ACP grading system, which is based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) method. Target Audience and Patient Population: The target audience for this guideline includes all clinicians, and the target patient population includes adults with joint inflammation suspected to be gout. Recommendation: ACP recommends that clinicians use synovial fluid analysis when clinical judgment indicates that diagnostic testing is necessary in patients with possible acute gout. (Grade: weak recommendation, low-quality evidence)
Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Children’s Cancer Group (CCG) Clinical Trial 1991 (CCG-1991).
Authors: Yousif Matloub, Anne Angiolillo, Bruce Bostrom, Stephen P. Hunger, James Nachman, Harland Sather, William L. Carroll, Naomi Winick, Paul S. Gaynon
Journal: Blood (2006)
New app for COPD patients is among innovation tariff’s six new technologies
Authors: Jacqui Wise
Journal: BMJ (2016)

NHS England has announced the first six medical innovations to be included in a new fast track payment scheme.1 These include an app to improve self management of chronic obstructive pulmonary disease, angled scissors to reduce tears during episiotomy, and new treatments for Clostridium difficile infection and benign prostatic hyperplasia.

The innovation and technology tariff aims to improve access to cutting edge technologies by removing the need for multiple local price negotiations and guaranteeing automatic reimbursement. NHS England will be able to negotiate bulk …
Association Between Metabolic Syndrome Components and Polyneuropathy in an Obese Population
Authors: Brian C. Callaghan, Rong Xia, Evan Reynolds, Mousumi Banerjee, Amy E. Rothberg, Charles F. Burant, Emily Villegas-Umana, Rodica Pop-Busui, Eva L. Feldman
Journal: JAMA Neurology (2016)

Past studies have shown an association between metabolic syndrome and polyneuropathy, but the precise components that drive this association remain unclear.To determine the prevalence of polyneuropathy stratified by glycemic status in well-characterized obese and lean participants and investigate the association of specific components of metabolic syndrome with polyneuropathy.We performed a cross-sectional, observational study from November 1, 2010, to December 31, 2014, in obese participants (body mass index [calculated as weight in kilograms divided by height in meters squared] of 35 or more with no comorbid conditions or 32 or more with at least 1 comorbid condition) from a weight management program and lean controls from a research website. The prevalence of neuropathy, stratified by glycemic status, was determined, and a Mantel-Haenszel χ2 test was used to investigate for a trend. Logistic regression was used to model the primary outcome of polyneuropathy as a function of the components of metabolic syndrome after adjusting for demographic factors. Participants also completed quantitative sudomotor axon reflex testing, quantitative sensory testing, the neuropathy-specific Quality of Life in Neurological Disorders instrument, and the short-form McGill Pain Questionnaire.Components of metabolic syndrome (as defined by the National Cholesterol Education Program Adult Treatment Panel III), including glycemic status (as defined by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus).Toronto consensus definition of probable polyneuropathy. Secondary outcomes included intraepidermal nerve fiber density and nerve conduction study parameters.We enrolled 102 obese participants (mean [SD] age, 52.9 [10.2] years; 48 men and 54 women; 45 with normoglycemia [44.1%], 31 with prediabetes [30.4%], and 26 with type 2 diabetes [25.5%]) and 53 lean controls (mean [SD] age, 48.5 [9.9] years; 16 men and 37 women). The prevalence of polyneuropathy was 3.8% in lean controls (n = 2), 11.1% in the obese participants with normoglycemia (n = 5), 29% in the obese participants with prediabetes (n = 9), and 34.6% in the obese participants with diabetes (n = 9) (P < .01 for trend). Age (odds ratio, 1.09; 95% CI, 1.02-1.16), diabetes (odds ratio, 4.90; 95% CI, 1.06-22.63), and waist circumference (odds ratio, 1.24; 95% CI, 1.00-1.55) were significantly associated with neuropathy in multivariable models. Prediabetes (odds ratio, 3.82; 95% CI, 0.95-15.41) was not significantly associated with neuropathy.The prevalence of polyneuropathy is high in obese individuals, even those with normoglycemia. Diabetes, prediabetes, and obesity are the likely metabolic drivers of this neuropathy.clinicaltrials.gov Identifier: NCT02689661.
Expression of the fetal hematopoiesis regulator FEV indicates leukemias of prenatal origin
Authors: T-H Liu, Y-J Tang, Y Huang, L Wang, X-L Guo, J-Q Mi, L-G Liu, H Zhu, Y Zhang, L Chen, X Liu, L-H Zhang, Q-J Ye, B-S Li, J-Y Tang, A Ford, T Enver, F Liu, G-Q Chen, D-L Hong
Journal: Leukemia (2016)
Inhibition of Fatty Acid Oxidation Leads to Apoptosis of Resting and Proliferating Chronic Lymphocytic Leukemia Cells in Vitro
Authors: Davorka Messmer, Kymmy Lorrain, Yalda Bravo, Nicholas Stock, Richard Bundey, Lucia Correa, Michael M Poon, Karin Stebbins, Geraldine Cabrera, Austin Chen, Jason Jacintho, David Spaner, Peppi Prasit, Daniel Lorrain
Journal: Blood (2012)
A National Registry of Patients Diagnosed with Multiple Myeloma in Taiwan.
Authors: Tzeon-Jye Chiou, Shang-Yi Huang, Cheng-Shyong Chang, Sheng-Fung Lin, Sung-Nan Pei, Chang-Fang Chiu, Ching-Liang Ho, Ming-Chih Chang, Tran-Der Tan, Liang-Tsai Hsiao
Journal: Blood (2009)
Tracking clonal diversity in metastatic prostate cancer progression.
Authors: Christopher Hovens, Matthew Hong, Geoff Macintyre, David Wedge, Peter Van Loo, Sebastian LunkePhD, Ludmil Alexandrov, Clare Slogget, Marek Cmero, Steafano Mangiola, Andrew Lonie, Haroon Naeem, Nikhil Sapre, Pramit Phal, Michael Kerger, John Pedersen, Andrew Ryan, Izhak Haviv, Anthony Costello, Niall Corcoran
Journal: Journal of Clinical Oncology (2015)

193 Background: Genomic heterogeneity has been observed in a number of tumor types including prostate cancer. However, how subclonal tumor diversity changes during metastasis and progression to lethality remains unexplored. Large scale genomic analyses have reported the most prevalent somatic aberrations associated with the dominant clone of the tumor without permitting an analysis of subclonal complexity or how this complexity impinges on metastatic potential or resistance to treatment. Methods: To understand and track the evolution of lethal prostate cancer from initial therapy to end stage metastases, we performed longitudinal and multiregional sampling of tumors from 7 patients with lethal prostate cancer. We performed whole-genome sequencing, RNA sequencing, and SNP profiling. Computational approaches were used to reconstruct the genetic relationships and evolution of the tumors. These evolutionary tree reconstructions allowed us to observe the dynamics of chromoplexy and mutational processes along specific branches of tumor evolution. To refine the genetic landscape and spatial connections between subclones, we employed deep, targeted re-sequencing of variant loci in the original sequenced samples, in additional FFPE sites sampled from the organ confined tumors, and from blood. Results: We show that while all primary and metastatic prostate tumors share a single ancestral clone, metastases arise from subclones present at minor frequencies in the primary tumor. We reveal that individual metastases comprise mixtures of subclones indicative of intra-metastatic heterogeneity. We provide evidence for cross-metastatic site seeding and dynamic remolding of subclonal mixtures in response to therapy suggesting a distinct metastatic hierarchy. Ultra-deep sequencing of end-stage blood reveals the presence of diverse subclones with metastatic potential derived from various stages in the evolution of the tumor. Conclusions: Our results demonstrate unexpected complexity in the origins of both primary and metastatic prostate cancer, with distinct implications for treatment of advanced disease.
Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.
Authors: Ruth Pettengell, Pier Luigi Zinzani, Geetha Narayanan, Fernando Hurtado de Mendoza, Raghunadharao Digumarti, Henry Gomez, Bertrand Coiffier, Gary Schiller, David A. Rizzieri, Paul Cernohous, Lixia Wang, Jack Singer
Journal: Blood (2010)
CBM-11EXOSOMAL AND CLINICAL ANALYSIS OF EGFR AMPLIFICATION AND EGFRvIII EXPRESSION IN INDIAN GLIOMA PATIENTS
Authors: Sasidhar V. Manda, Babul Reddy Tatireddy, Yogesh Kataria, Alok Ranjan, Amitava Ray
Journal: Neuro-Oncology (2015)

BACKGROUND: Molecular profiling of brain tumors is currently performed through tissue biopsy, which is risky, and also inaccurate due to tumor heterogeneity. It has been shown that non-invasive profiling can be performed using exosomes. Exosomes are nano shuttles harboring both RNA and DNA from the cell of origin. In this report we present an optimized clinical detection method for profiling brain tumors. We used serum exosomes to detect the presence of a tumor specific EGFRvIII, a splice variant of the Epidermal growth factor receptor (EGFR) receptor, and a target of several anti-cancer products, including Rindopepimut. METHODS: Serum and paired glioma tissue biopsies with a confirmed histopathology were collected as per approved ethics protocol. RNA was isolated using commercial kits (Invitrogen). Quantification of wild-type EGFR and EGFRvIII variant expression was performed using a semi-nested PCR with GAPDH as an internal control. Paired biopsy tissue is used as an internal control for comparison. Additionally EGFR amplification was also performed by Vysis EGFR/CEP7 FISH. We also performed overall survival analysis using Kaplan –Meier Survival curve analysis. Clinical pathology was correlated with tissue and exosomal EGFRvIII expression. Comparisons between groups were performed using student t-tests. Survival differences between groups were compared using the log-rank test. RESULTS: Tumor specific EGFRvIII was detected by PCR in 26 of 73 glioma samples and confirmed by sequencing. Exosomal EGFRvIII detection is absent in healthy controls. Distinct expression profile in exosomal EGFRvIII expression was observed among different grades of glioma. Exosomal EGFRvIII detection rate is more prominent in patients exhibiting wild-type EGFR, detected through FISH and PCR. Overall-survival is independent of EGFR wild type or EGFRvIII expression. CONCLUSION: The above data indicate that exosomes may have a utility in detecting brain tumors through simple blood test without an invasive biopsy. Further validation is needed for regular clinical use.
ATPS-55INFLUENCE OF MAPK AND PI3K PATHWAY MUTATIONS ON RESPONSE TO TARGETED INHIBITORS
Authors: Robert S. McNeill, Demitra A. Canoutas, Ralf S. Schmid, Ryan E. Bash, Brian H. Constance, Salma H. Azam, Rachel A. Reuther, Gary L. Johnson, C. Ryan Miller
Journal: Neuro-Oncology (2015)

RTK/MAPK/PI3K pathway genes are mutated in 90% of glioblastomas.It remains unclear whether targeted inhibitor response is predicted by mutation status.We addressed this issue using isogenic, immortalized mouse and human astrocytes with and without MAPK and/or PI3K mutations.MEK inhibitors showed variable potency (GSK1120212 .PD0325901 .AZD6244) in vitro.Efficacy was independent of MAPK mutations, but increased 2 -66 fold with PI3K mutations.In contrast, PI3K inhibitor efficacy (BKM120 .LY294002) was increased 1.5-5 fold when MAPK, PI3K, or both were mutated.We used multiplexed inhibitor bead-mass spectrometry kinome profiling to show that monotherapy efficacy is limited by adaptive kinome responses, including inhibited pathway reactivation and bypass pathway activation.BKM120 induced sustained inhibition of proximal PI3K in mouse astrocytes with mutated MAPK/PI3K (TRP), but distal PI3K reactivation and MAPK activation limited its efficacy.Conversely, AZD6244 induced sustained MAPK inhibition, but also activated PI3K.These findings suggested that MAPK and PI3K were reciprocal, bypass pathways that promote monotherapy resistance.However, dual AZD6244/BKM120 therapy was synergistic in vitro at therapeutic concentrations in cells with mutated MAPK, PI3K, or both.Next, we examined efficacy in an orthotopic, TRP astrocyte allograft model of glioblastoma using maximum tolerated doses of AZD6244 (37 mpk), BKM120 (30 mpk), or both (reduced to 18 and 25 mpk due to toxicity).AZD6244 delayed tumor growth and improved survival compared to control, but BKM120 and dual treatment did not (doubling time 4.1, 2.2, 2.3 vs. 2.3 days; median survival 27, 24, 21 vs. 25 days).Only AZD6244 inhibited targeted pathway signaling in treated tumors, suggesting that BKM120 or dual therapy efficacy was limited by drug bioavailability or potency.Taken together, these results indicate that dual therapy, particularly in tumors with genetically activated MAPK and PI3K signaling, may prove beneficial if sufficient drug bioavailability and potency is achieved.
Progressive Decline of Lung Function in Rheumatoid Arthritis–Associated Interstitial Lung Disease
Authors: Jorge A. Zamora‐Legoff, Megan L. Krause, Cynthia S. Crowson, Jay H. Ryu, Eric L. Matteson
Journal: Arthritis & Rheumatology (2016)

Interstitial lung disease (ILD) is associated with substantial morbidity in rheumatoid arthritis (RA), but very little is known about its long-term progression. This study was undertaken to investigate the progression of pulmonary disease using a large single-center cohort of patients with RA-associated ILD.Records of all patients with RA-associated ILD seen at Mayo Clinic between 1998 and 2014, with at least 4 weeks follow-up and at least 1 pulmonary function test, were identified and manually screened for study inclusion. Progression was defined as a diffusing capacity for carbon monoxide (DLco) <40% predicted (or patients whose illness was too advanced to undergo screening) or a forced vital capacity (FVC) <50% predicted. Time to progression was analyzed using the Kaplan-Meier method.Of the 167 patients included in the study, 81 (49%) were female, with a mean ± SD age of 67 ± 10 years at diagnosis of ILD. Median follow-up time from diagnosis of ILD was 3.3 years (range 0.01-14.8). One-third of the patients required supplemental oxygen, 40% developed DLco <40% predicted, and 22% developed FVC <50% predicted within 5 years after ILD diagnosis. Usual interstitial pneumonia (UIP) versus nonspecific interstitial pneumonia (NSIP) was a risk factor for DLco progression (hazard ratio 3.29 [95% confidence interval 1.28-8.41]). Lower DLco and FVC at baseline increased the risk for progression to DLco <40% predicted and FVC <50% predicted, and higher rates of change in the first 6 months also increased the risk of progression.Progressive loss of pulmonary function is common in RA-associated ILD and is worse in patients with UIP than in those with NSIP. Predictors of progression in patients with RA-associated ILD may aid clinicians in identifying patients at highest risk for progression of ILD.
Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course
Authors: S. Boeck, Y. Mehraein, S. Ormanns, S. Kruger, C.Benedikt Westphalen, M. Haas, A. Jung, T. Kirchner, V. Heinemann
Journal: Annals of Oncology (2016)
Effects Of a Novel Ceramic Biomaterial On Immune Modulatory Properties and Differentiation Potential Of Mesenchymal Stromal Cells
Authors: Giulio Bassi, Cedric Menard, Fabien Guilloton, Luciano Pacelli, Roberta Carusone, Mariano Di Trapani, Jasmina Zanoncello, Francesco Bifari, Luc Sensebé, Fredric Deschaseaux, Serge Baroth, Hubert Schrezenmeier, Markus Rojewski, Pierre Layrolle, Rosaria Giordano, Lazzari Lorenza, Cristiana Lavazza, Philippe Bourin, Karin Tarte, Mauro Krampera
Journal: Blood (2013)
Diagnostic Dilemmas in Oncology
Authors: Thomas Gergel, Gary Proulx, Lawrence Leichman, Hector Nava, Michael Kuettel
Journal: Journal of Clinical Oncology (2001)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.23.4344 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11731519 Diagnostic Dilemmas in Oncology Case 3. Pericardial Effusion After Esophageal Radiation Thomas GergelxThomas GergelSearch for articles by this author , Gary ProulxxGary ProulxSearch for articles by this author , Lawrence LeichmanxLawrence LeichmanSearch for articles by this author , Hector NavaxHector NavaSearch for articles by this author , Michael KuettelxMichael KuettelSearch for articles by this author Show More Roswell Park Cancer Institute, Buffalo, NY https://doi.org/10.1200/JCO.2001.19.23.4344 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical Oncology
The Feature of TCR Vβ Repertoire, Thymic Recent Output Function and TCR-zeta Chain Expression in Patients with Immune Thrombocytopenic Purpura.
Authors: Xueli Zhang, Yangqiu Li, Shaohua Chen, Lijian Yang, Si Chen, Xiuli Wu, Tao Zhang, Jun Zhong, Kanger Zhu
Journal: Blood (2007)
Sustained Growth of Primary Myeloma Cells in Coculture with Whole Donor Bone Marrow Is Associated with Induced Secretion of the Microenvironmental Mediator of Cytokinesis, Hemicentin-1
Authors: Rakesh Bam, Ricky D Edmondson, Caleb K Stein, Xin Li, Wen Ling, Sharmin Khan, Randal S Shelton, Bart Barlogie, Shmuel Yaccoby
Journal: Blood (2014)
The Effect of Quinine on the Production of Gametocytes in Subtertian Malaria.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Molecular Mutations in U2AF1 Are Most Commonly Found in Del20q Myelodysplastic Syndromes but Do Not Lead to Poor Prognosis in This Karyotypic Subtype
Authors: Ali Tabarroki, Li Zhang, Valeria Visconte, Manoj Bupathi, Heesun J. Rogers, Hideki Makishima, Fabiola Traina, Betty K. Hamilton, Edy Hasrouni, Michael J. Clemente, Paula de Melo Campos, Hien K. Duong, Anjali Advani, Mikkael A. Sekeres, Edward A. Copelan, Ramon V. Tiu
Journal: Blood (2012)
Ocular Syphilis — Eight Jurisdictions, United States, 2014–2015
Authors: Sara E. Oliver, Mark Aubin, Leah Atwell, James Matthias, Anna Cope, Victoria Mobley, Alexandra Goode, Sydney Minnerly, Juliet Stoltey, Heidi M. Bauer, Robin R. Hennessy, Dawne DiOrio, Robyn Neblett Fanfair, Thomas A. Peterman, Lauri Markowitz
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Ocular syphilis, a manifestation of Treponema pallidum infection, can cause a variety of ocular signs and symptoms, including eye redness, blurry vision, and vision loss. Although syphilis is nationally notifiable, ocular manifestations are not reportable to CDC. Syphilis rates have increased in the United States since 2000. After ocular syphilis clusters were reported in early 2015, CDC issued a clinical advisory (1) in April 2015 and published a description of the cases in October 2015 (2). Because of concerns about an increase in ocular syphilis, eight jurisdictions (California, excluding Los Angeles and San Francisco, Florida, Indiana, Maryland, New York City, North Carolina, Texas, and Washington) reviewed syphilis surveillance and case investigation data from 2014, 2015, or both to ascertain syphilis cases with ocular manifestations. A total of 388 suspected ocular syphilis cases were identified, 157 in 2014 and 231 in 2015. Overall, among total syphilis surveillance cases in the jurisdictions evaluated, 0.53% in 2014 and 0.65% in 2015 indicated ocular symptoms. Five jurisdictions described an increase in suspected ocular syphilis cases in 2014 and 2015. The predominance of cases in men (93%), proportion of those who are men who have sex with men (MSM), and percentage who are HIV-positive (51%) are consistent with the epidemiology of syphilis in the United States. It is important for clinicians to be aware of potential visual complications related to syphilis infections. Prompt identification of potential ocular syphilis, ophthalmologic evaluation, and appropriate treatment are critical to prevent or manage visual symptoms and sequelae of ocular syphilis.
The Decrease of Regulatory T Cells through the Low Levels of FOXP3 Expression Mediated by NFAT1 in Infancy with Autoimmune Neutropenia.
Authors: Kazuhiro Nakamura, Mizuka Miki, Syuhei Karakawa, Rie Onodera, Emi Kurita, Asako Hiraoka, Takashi Sato, Masao Kobayashi
Journal: Blood (2007)
The Change of Vascular Endothelial Growth Factor and Microvessel Density Following Imatinib Mesylate Therapy and Allogeneic Bone Marrow Transplantation in Chronic Myeolid Leukemia.
Authors: Jae-Yong Kwak, Na-Ri Lee, Eun-Gi Song, Chang-Yeol Yim, Myoung-Ja Chung, Yong-Gon Jo, Sam-Im Choi
Journal: Blood (2004)